HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
Antonio Llombart‐Cussac(MedSIR (Spain)), Aleix Prat(Hospital Clínic de Barcelona), Begoña Bermejo(Hospital Clínico Universitario de Valencia), Sònia Pernas, Javier Cortés(Villa Maria Hospital), Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Alexandra Peláez, Patricia Galván(Vall d'Hebron Institute of Oncology), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Noelia Martínez-Jáñez(Instituto Cajal), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Serafín Morales(Hospital Universitari Arnau de Vilanova), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), María Vidal(Inserm), Lorena de la Peña, Rafael López‐López(Universidade de Santiago de Compostela)
Cited by 340
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k